Evidence map›Paper›PMID 28600117›Full record

Trial reportSurgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery2017

Long-term effects of bariatric surgery in patients with obesity and chromosome 16 p11.2 microdeletion.

Felipe M Kristensson, Johanna C Andersson-Assarsson, Noora Kanerva, Markku Peltonen, Björn Carlsson, Lena M S Carlsson

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Felipe M KristenssonInstitute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Johanna C Andersson-AssarssonInstitute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. Electronic address: johanna.andersson@medic.gu.se.
Noora KanervaInstitute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Health, National Institute for Health and Welfare, Helsinki, Finland.
Markku PeltonenDepartment of Health, National Institute for Health and Welfare, Helsinki, Finland.
Björn CarlssonInstitute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Innovative Medicines and Early Development Biotech Unit, AstraZeneca Gothenburg, Mölndal, Sweden.
Lena M S CarlssonInstitute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
University of Gothenburg · SEFinnish Institute for Health and Welfare · FIAstraZeneca (Sweden) · SE

Funding

Benefits, Risks & Costs of Bariatric Surgery: Register-Enriched Cohort Studies.R01DK105948 · NIDDK · GOTEBORG UNIVERSITY · PI CARLSSON EKANDER, LENA, NEOVIUS, MARTIN · 2015 to 2018
$1.8M
NIDDK NIH HHS R01 DK105948
6 · The paper itself

Abstract

backgroundChromosome 16 p11.2 microdeletion is associated with early-onset obesity. Information is limited about the effect of bariatric surgery in patients with genetic obesity.

objectiveTo examine the effects of bariatric surgery in obese patients with chromosome 16 p11.2 microdeletion.

settingAcademic research institution.

methodsThe Swedish Obese Subjects study is a prospective study with 2010 participants receiving bariatric surgery. DNA was available for 1843 participants. Multiplex ligation-dependent probe amplification was used to identify 16 p11.2 microdeletion carriers. Follow-up time was 10 years. In carriers and noncarriers, follow-up rate was 86% and 82%, respectively, at 10 years.

resultsNine carriers of the chromosome 16 p11.2 microdeletion (9/1843, .49%) were found. At baseline, most risk factors were similar; however, carriers had higher body mass index (BMI), insulin levels, and systolic blood pressure compared to noncarriers. At the 1-year examination, the percent excess BMI lost (%EBMIL) in carriers and noncarriers was 71.9 and 62.2, respectively; P = .031 (37.9 and 30.6 kg). This was followed by partial weight regain in both groups, and after 10 years %EBMIL was 25.5 and 41.5 (15.7 and 21.3 kg), respectively (P = .377). Changes in risk factors were similar in the carriers and noncarriers. Two carriers who had type 2 diabetes at baseline were both in remission at 2-year follow-up but relapsed at 10-year follow-up. Perceived health status was similar in carriers and noncarriers during follow-up (overall P = .198).

conclusionsDespite a small sample size, our results indicate that bariatric surgery is a treatment option for obese patients with chromosome 16 p11.2 microdeletion.

Indexed as

Chromosome DeletionAdultBariatric SurgeryBody WeightChromosomes, Human, Pair 16Diabetes Mellitus, Type 2Energy IntakeFemaleHealth StatusHeterozygoteHumansMaleMiddle AgedObesity, MorbidPolymorphism, Single NucleotidePostoperative ComplicationsBariatric surgeryChromosome 16 p11.2 microdeletionObesity

Identifiers

PMID28600117
PMCPMC5656385
OpenAlexW2608058488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.